Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026
Fractyl Health (Nasdaq: GUTS), a clinical-stage metabolic therapeutics company focused on obesity and type 2 diabetes, announced it will report its second quarter 2026 financial results and provide business updates on Monday, August 10, 2026, at 4:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Fractyl Health (Nasdaq: GUTS), a clinical-stage metabolic therapeutics company focused on obesity and type 2 diabetes, announced it will report its second quarter 2026 financial results and provide business updates on Monday, August 10, 2026, at 4:30 p.m. ET.
According to Fractyl Health, investors and the public can access a live webcast of the conference call and presentation in the “Events” section of its investor relations website at http://ir.fractyl.com. The webcast will be archived for replay after the live event.
Details
News Market Reaction – GUTS
On Aug 4, the first trading day after this news, GUTS closed 1.15% above the previous close.
Data tracked by StockTitan Argus for the Aug 4 session.
Key Figures
- Reporting period
- Q2 2026
- Financial results to be reported
- Report date
- August 10, 2026
- Scheduled results announcement
- Conference time
- 4:30 p.m. ET
- Scheduled webcast and presentation
Previous Earnings date Reports
-
Prior announcement scheduled fourth-quarter and full-year 2025 results for March 24, 2026.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
t2d medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will report financial results for the second quarter 2026 and provide business updates on Monday, August 10, 2026, at 4:30 p.m. ET.
A live webcast of the conference call and presentation can be accessed in the “Events” section of Fractyl Health’s website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event.
About Fractyl Health
Fractyl Health is a clinical-stage metabolic therapeutics company advancing two differentiated candidates designed to target the root causes of obesity and T2D: Revita, a procedural therapy in pivotal development for post-GLP-1 weight maintenance, and Rejuva, an AAV-based gene therapy platform with its lead candidate RJVA-001 entering first-in-human clinical studies. Fractyl’s goal is to advance metabolic disease treatment from chronic management toward prevention and reversal of disease. Fractyl is headquartered in Burlington, Massachusetts.
Contact
Brian Luque, Head of Investor Relations and Corporate Development
IR@fractyl.com, 951.206.1200
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.